Log in to save to my catalogue

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separa...

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separa...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1746889035

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

About this item

Full title

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2015-04, Vol.385 (9977), p.1545-1554

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Ebola virus and Marburg virus cause serious disease outbreaks with high case fatality rates. We aimed to assess the safety and immunogenicity of two investigational DNA vaccines, one (EBO vaccine) encoding Ebola virus Zaire and Sudan glycoproteins and one (MAR) encoding Marburg virus glycoprotein. Methods RV 247 was a phase 1b, d...

Alternative Titles

Full title

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1746889035

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1746889035

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(14)62385-0

How to access this item